TrialBlood2018

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.

Romanos Sklavenitis-Pistofidis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.